Biomedical subjects
Paul Smith
Publications and source records attributed to Paul Smith.
Budding talents.
Explore the source record for details and available documents.
Vacant expression.
Explore the source record for details and available documents.
Dichroic ultraviolet light filters.
With the intention to produce dichroic filters for use in photoluminescent systems that rely on polarized UV light, we synthesized a number of linear, dichroic dyes, which absorb mainly in the near-UV range of the electromagnetic spectrum. These dyes were designed for compatibility with common thermoplastic polymers such as linear low-density poly(ethylene), poly(ethylene terephthalate), and polyamide-12. Films of these host polymers that consisted of 0.2% by weight of various dichroic UV dyes were produced by common melt-processing schemes. Uniaxial drawing of these films yielded highly dichroic UV filters with dichroic ratios in absorption that in some cases exceeded 100. The fact that these free-standing films display little or no coloration and are environmentally stable makes them useful for various applications that involve generation of polarized UV light.
It takes all sorts.
Explore the source record for details and available documents.
History in the making.
Explore the source record for details and available documents.
CHI review. An inspector calls.
Explore the source record for details and available documents.
Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase.
Tumor ganglioside metabolism has been implicated in modulating tumor formation and progression. We found previously that transient ganglioside depletion by inhibition of glucosylceramide synthesis of MEB4 melanoma cells in vitro reduced their tumorigenic capability. Here, we have established that treatment of the host with a novel p.o. inhibitor of glucosylceramide synthesis, the imino sugar OGT2378, inhibits MEB4 melanoma tumor growth in a syngeneic, orthotopic murine model. The glucosylceramide and ganglioside content of MEB4 cells exposed to 20 micro M OGT2378 in culture were reduced by 93 and >95%, respectively, without either cytotoxic or antiproliferative effects. Administered in the diet to C57BL/6 mice, 2500 mg/kg/day OGT2378 was well tolerated in vivo and biologically active, depleting host tissue (hepatic) gangliosides by 82% and tumor gangliosides by >98%. p.o. treatment with OGT2378 starting 3 days before intradermal tumor inoculation of 4 x 10(4) MEB4 cells, and continuing for 4 weeks, resulted in a 10-fold lower mean tumor volume at the end of treatment (60 versus 538 mm(3), P < 0.0001). Even when OGT2378 treatment was initiated 7 days after tumor inoculation, tumor growth was similarly impeded (61 versus 620 mm(3), P < 0.0001), demonstrating an effect on an established tumor. The effectiveness of p.o. OGT2378 in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising and now feasible novel therapeutic approach to inhibit tumor progression.
That was the week that was.
Explore the source record for details and available documents.
A quiet word.
Explore the source record for details and available documents.
Overseas, over here.
Explore the source record for details and available documents.